Guidance from Public Health England (PHE) on the supply of naloxone following the updates to ‘The Human Medicines Regulations 2019’. This guidance now includes the ability for UK drug services to supply nasal naloxone.
The 2019 law amendments on the provision of take home naloxone in the UK, which, among other things, allow for the supply of intranasal naloxone.
More than 9 000 lives were reported to be lost to drug overdoses in Europe (28 EU Member States, Turkey and Norway) in 2016, the latest reporting year, and this is an underestimate. Reducing drug-related deaths therefore remains a major challenge for public health policy. This analysis describes some of the factors that increase the risk of fatal and non-fatal overdoses and a number of interventions developed to prevent these events. Part of the ‘Perspectives on drugs’ (PODs) series, launched alongside the annual European Drug Report, these designed-for-the-web interactive analyses aim to provide deeper insights into a selection of important issues.
This short animation from SAMHSA depicts how Naloxone, an opioid overdose-reversal medication, works in the body.
The 2018 report from the European Monitoring Centre for Drugs and Drug Addiction has been released, this report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses.
The Improving Outcomes in the Treatment of Opioid Dependence (IOTOD) educational initiative have released a Take Home Naloxone toolkit including training materials and other resources to help you start a THN programme.
